Seeing Is Believing
Currently out of the existing stock ratings of Tejas Savant, 101 are a HOLD (37.13%), 15 are a SELL (5.51%), 156 are a BUY (57.35%).
Analyst Tejas Savant, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 44.26% that have a potential upside of 31.74% achieved within 160 days.
Tejas Savant’s has documented 558 price targets and ratings displayed on 34 stocks. The coverage is on Healthcare, Basic Materials, Industrials sectors.
Most recent stock forecast was given on ADPT, Adaptive Biotechnologies Corp at 02-Dec-2025.
Analyst best performing recommendations are on CTKB (CYTEK BIOSCIENCES).
The best stock recommendation documented was for CTKB (CYTEK BIOSCIENCES) at 2/29/2024. The price target of $9 was fulfilled within 1 day with a profit of $1.3 (16.88%) receiving and performance score of 168.83.
Average potential price target upside
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
Since 09-Sep-2020
$21
$3.48 (19.86%)
$16
1 months 17 days ago
(02-Dec-2025)
8/9 (88.89%)
$2.16 (11.46%)
581
Buy
Since 07-Oct-2020
$19
$1.48 (8.45%)
$9
2 months 28 days ago
(22-Oct-2025)
6/9 (66.67%)
$2.55 (15.50%)
96
Buy
Since 08-Aug-2023
$20
$2.48 (14.16%)
$15
3 months 4 days ago
(15-Oct-2025)
15/15 (100%)
$2.89 (16.89%)
303
Buy
Since 21-Mar-2025
$10
$-7.52 (-42.92%)
$9
8 months 17 days ago
(02-May-2025)
5/6 (83.33%)
$0.16 (1.63%)
96
Buy
Since 05-Jan-2023
$12
$-5.52 (-31.51%)
$15
11 months 6 days ago
(13-Feb-2025)
2/2 (100%)
$3.48 (40.85%)
570
Which stock is Tejas Savant is most bullish on?
Which stock is Tejas Savant is most reserved on?
What Year was the first public recommendation made by Tejas Savant?